CA2100355A1 - Enzyme de conversion de l'endotheline - Google Patents

Enzyme de conversion de l'endotheline

Info

Publication number: CA2100355A1
Authority: CA; Canada
Prior art keywords: protein; endothelin; ece; activity; enzyme
Prior art date: 1991-02-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2100355

Other languages

English (en)

Inventor

Lynne H. Parker Botehlo

Maria C. Garrigan

Anthony Johns

Barry L. Levinson

Kathleen C. Patterson

Mark A. Polokoff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Berlex Laboratories Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-04

Filing date

1992-02-04

Publication date

1992-08-05

1992-02-04 Application filed by Individual filed Critical Individual

1992-08-05 Publication of CA2100355A1 publication Critical patent/CA2100355A1/fr

Status Abandoned legal-status Critical Current

Links

102000048186 Endothelin-converting enzyme 1 Human genes 0.000 title claims abstract description 18
108030001679 Endothelin-converting enzyme 1 Proteins 0.000 title claims abstract description 18
108090000623 proteins and genes Proteins 0.000 claims description 90
102000004169 proteins and genes Human genes 0.000 claims description 78
108050009340 Endothelin Proteins 0.000 claims description 71
102000002045 Endothelin Human genes 0.000 claims description 70
230000000694 effects Effects 0.000 claims description 69
ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 claims description 68
210000004027 cell Anatomy 0.000 claims description 49
238000000034 method Methods 0.000 claims description 40
102000004190 Enzymes Human genes 0.000 claims description 33
108090000790 Enzymes Proteins 0.000 claims description 33
238000006243 chemical reaction Methods 0.000 claims description 25
150000001413 amino acids Chemical group 0.000 claims description 22
239000012528 membrane Substances 0.000 claims description 20
101800004490 Endothelin-1 Proteins 0.000 claims description 18
229920002684 Sepharose Polymers 0.000 claims description 17
238000003776 cleavage reaction Methods 0.000 claims description 16
-1 phenylmethoxy Chemical group 0.000 claims description 16
230000007017 scission Effects 0.000 claims description 16
239000000126 substance Substances 0.000 claims description 15
150000001875 compounds Chemical class 0.000 claims description 12
HZZGDPLAJHVHSP-GKHTVLBPSA-N big endothelin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]2CSSC[C@@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CSSC1)C1=CN=CN1 HZZGDPLAJHVHSP-GKHTVLBPSA-N 0.000 claims description 11
229910021645 metal ion Inorganic materials 0.000 claims description 11
238000012216 screening Methods 0.000 claims description 10
230000004071 biological effect Effects 0.000 claims description 8
108090000765 processed proteins & peptides Proteins 0.000 claims description 7
ZPHBZEQOLSRPAK-UHFFFAOYSA-N Phosphoramidon Natural products C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O ZPHBZEQOLSRPAK-UHFFFAOYSA-N 0.000 claims description 5
108010072906 phosphoramidon Proteins 0.000 claims description 5
BWSDNRQVTFZQQD-AYVHNPTNSA-N phosphoramidon Chemical compound O([P@@](O)(=O)N[C@H](CC(C)C)C(=O)N[C@H](CC=1[C]2C=CC=CC2=NC=1)C(O)=O)[C@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@@H]1O BWSDNRQVTFZQQD-AYVHNPTNSA-N 0.000 claims description 5
210000000329 smooth muscle myocyte Anatomy 0.000 claims description 5
239000011701 zinc Substances 0.000 claims description 5
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
102000004196 processed proteins & peptides Human genes 0.000 claims description 4
230000007928 solubilization Effects 0.000 claims description 4
238000005063 solubilization Methods 0.000 claims description 4
230000003381 solubilizing effect Effects 0.000 claims description 4
229910052725 zinc Inorganic materials 0.000 claims description 4
238000005349 anion exchange Methods 0.000 claims description 3
230000002401 inhibitory effect Effects 0.000 claims description 3
102000006410 Apoproteins Human genes 0.000 claims description 2
108010083590 Apoproteins Proteins 0.000 claims description 2
239000003957 anion exchange resin Substances 0.000 claims description 2
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
102000003729 Neprilysin Human genes 0.000 description 46
108090000028 Neprilysin Proteins 0.000 description 46
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 44
229940088598 enzyme Drugs 0.000 description 30
238000000746 purification Methods 0.000 description 29
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
239000011780 sodium chloride Substances 0.000 description 22
238000003556 assay Methods 0.000 description 21
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 20
239000000872 buffer Substances 0.000 description 16
229940024606 amino acid Drugs 0.000 description 15
238000004519 manufacturing process Methods 0.000 description 15
239000000463 material Substances 0.000 description 15
239000008188 pellet Substances 0.000 description 13
239000000047 product Substances 0.000 description 13
239000003112 inhibitor Substances 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
239000000523 sample Substances 0.000 description 12
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
239000003599 detergent Substances 0.000 description 10
239000000499 gel Substances 0.000 description 10
239000000203 mixture Substances 0.000 description 10
239000000758 substrate Substances 0.000 description 10
102100030988 Angiotensin-converting enzyme Human genes 0.000 description 9
238000005194 fractionation Methods 0.000 description 9
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
102000035195 Peptidases Human genes 0.000 description 8
108091005804 Peptidases Proteins 0.000 description 8
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 8
239000001632 sodium acetate Substances 0.000 description 8
235000017281 sodium acetate Nutrition 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
239000004365 Protease Substances 0.000 description 7
238000010828 elution Methods 0.000 description 7
241000894007 species Species 0.000 description 7
108010052285 Membrane Proteins Proteins 0.000 description 6
230000002255 enzymatic effect Effects 0.000 description 6
239000002504 physiological saline solution Substances 0.000 description 6
239000002243 precursor Substances 0.000 description 6
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
102400000686 Endothelin-1 Human genes 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 5
239000001110 calcium chloride Substances 0.000 description 5
235000011148 calcium chloride Nutrition 0.000 description 5
229910001628 calcium chloride Inorganic materials 0.000 description 5
230000015556 catabolic process Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
102000005593 Endopeptidases Human genes 0.000 description 4
108010059378 Endopeptidases Proteins 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
238000001514 detection method Methods 0.000 description 4
238000002523 gelfiltration Methods 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
210000004072 lung Anatomy 0.000 description 4
238000012986 modification Methods 0.000 description 4
230000004048 modification Effects 0.000 description 4
230000002797 proteolythic effect Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000000243 solution Substances 0.000 description 4
101100004297 Caenorhabditis elegans bet-1 gene Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
239000007993 MOPS buffer Substances 0.000 description 3
102000005741 Metalloproteases Human genes 0.000 description 3
108010006035 Metalloproteases Proteins 0.000 description 3
102000001708 Protein Isoforms Human genes 0.000 description 3
108010029485 Protein Isoforms Proteins 0.000 description 3
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 3
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000002526 effect on cardiovascular system Effects 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000001742 protein purification Methods 0.000 description 3
238000004007 reversed phase HPLC Methods 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
239000011537 solubilization buffer Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
239000005541 ACE inhibitor Substances 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102400000687 Big endothelin-1 Human genes 0.000 description 2
101800001398 Big endothelin-1 Proteins 0.000 description 2
101000645291 Bos taurus Metalloproteinase inhibitor 2 Proteins 0.000 description 2
ZUBDGKVDJUIMQQ-VVTNISDDSA-N CC[C@H](C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H]2CSSC[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC2=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2ccccc2)C(=O)N1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(O)=O ZUBDGKVDJUIMQQ-VVTNISDDSA-N 0.000 description 2
206010007559 Cardiac failure congestive Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
229940122097 Collagenase inhibitor Drugs 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
108010066671 Enalaprilat Proteins 0.000 description 2
208000007530 Essential hypertension Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
206010019280 Heart failures Diseases 0.000 description 2
101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 2
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 2
102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
201000001068 Prinzmetal angina Diseases 0.000 description 2
208000001647 Renal Insufficiency Diseases 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
206010000891 acute myocardial infarction Diseases 0.000 description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
230000002547 anomalous effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
239000002738 chelating agent Substances 0.000 description 2
239000002442 collagenase inhibitor Substances 0.000 description 2
239000002299 complementary DNA Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
210000001198 duodenum Anatomy 0.000 description 2
229960002680 enalaprilat Drugs 0.000 description 2
LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 2
229940066758 endopeptidases Drugs 0.000 description 2
239000000727 fraction Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000010353 genetic engineering Methods 0.000 description 2
230000013595 glycosylation Effects 0.000 description 2
238000006206 glycosylation reaction Methods 0.000 description 2
210000002837 heart atrium Anatomy 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
201000006370 kidney failure Diseases 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
210000003712 lysosome Anatomy 0.000 description 2
230000001868 lysosomic effect Effects 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
150000007523 nucleic acids Chemical group 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
238000000053 physical method Methods 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
208000002815 pulmonary hypertension Diseases 0.000 description 2
239000013014 purified material Substances 0.000 description 2
238000000926 separation method Methods 0.000 description 2
230000035939 shock Effects 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
239000005526 vasoconstrictor agent Substances 0.000 description 2
REOCNKZXONOGGX-ABLWVSNPSA-N (2s)-2-[(2-carboxy-3-phenylpropanoyl)amino]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)C(C(O)=O)CC1=CC=CC=C1 REOCNKZXONOGGX-ABLWVSNPSA-N 0.000 description 1
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
101001006370 Actinobacillus suis Hemolysin Proteins 0.000 description 1
102000004400 Aminopeptidases Human genes 0.000 description 1
108090000915 Aminopeptidases Proteins 0.000 description 1
102000035101 Aspartic proteases Human genes 0.000 description 1
108091005502 Aspartic proteases Proteins 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
101100133184 Caenorhabditis elegans nep-1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000189662 Calla Species 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
102000003908 Cathepsin D Human genes 0.000 description 1
108090000258 Cathepsin D Proteins 0.000 description 1
102000004178 Cathepsin E Human genes 0.000 description 1
108090000611 Cathepsin E Proteins 0.000 description 1
108010062580 Concanavalin A Proteins 0.000 description 1
QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102100034866 Kallikrein-6 Human genes 0.000 description 1
239000004395 L-leucine Substances 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108020004711 Nucleic Acid Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102100032341 PCNA-interacting partner Human genes 0.000 description 1
101710196737 PCNA-interacting partner Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
241000270295 Serpentes Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
241000543700 Staphylococcus virus Twort Species 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
LWFWZRANSFAJDR-JSGCOSHPSA-N Trp-Val Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(O)=O)=CNC2=C1 LWFWZRANSFAJDR-JSGCOSHPSA-N 0.000 description 1
DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
210000000709 aorta Anatomy 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001638 cerebellum Anatomy 0.000 description 1
210000004720 cerebrum Anatomy 0.000 description 1
230000009920 chelation Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001805 chlorine compounds Chemical group 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
239000000539 dimer Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000001506 fluorescence spectroscopy Methods 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
238000000227 grinding Methods 0.000 description 1
238000000703 high-speed centrifugation Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229960003136 leucine Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
238000011068 loading method Methods 0.000 description 1
208000012866 low blood pressure Diseases 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
210000001767 medulla oblongata Anatomy 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000003475 metalloproteinase inhibitor Substances 0.000 description 1
HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002853 nucleic acid probe Substances 0.000 description 1
YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
235000019419 proteases Nutrition 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000000376 reactant Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000013037 reversible inhibitor Substances 0.000 description 1
239000012723 sample buffer Substances 0.000 description 1
238000003375 selectivity assay Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1
210000001644 umbilical artery Anatomy 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
239000013598 vector Substances 0.000 description 1
239000011800 void material Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6497—Endothelin-converting enzyme (3.4.24.71)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24071—Endothelin-converting enzyme 1 (3.4.24.71)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Enzymes And Modification Thereof (AREA)

CA 2100355 1991-02-04 1992-02-04 Enzyme de conversion de l'endotheline Abandoned CA2100355A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65039491A	1991-02-04	1991-02-04
US07/650,394		1991-02-04

Publications (1)

Publication Number	Publication Date
CA2100355A1 true CA2100355A1 (fr)	1992-08-05

Family

ID=24608722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2100355 Abandoned CA2100355A1 (fr)	1991-02-04	1992-02-04	Enzyme de conversion de l'endotheline

Country Status (3)

Country	Link
EP (1)	EP0575405A1 (fr)
CA (1)	CA2100355A1 (fr)
WO (1)	WO1992013944A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0545344B1 (fr) *	1991-11-29	1997-05-02	Nisshin Flour Milling Co., Ltd.	Enzymes de conversion d'endothéline
WO1994028012A1 (fr) *	1993-05-28	1994-12-08	Warner-Lambert Company	Hydroxamates inhibiteurs de l'enzyme de conversion de l'endotheline
IT1266570B1 (it) *	1993-07-30	1997-01-09	Zambon Spa	Derivati della propanammide n-eteroaril sostituiti utili nel trattamento delle malattie cardiovascolari
EP0638643A1 (fr) *	1993-08-13	1995-02-15	Nisshin Flour Milling Co., Ltd.	Enzyme de conversion de l'endotheline et procédé pour la produire
KR950008684A (ko) *	1993-09-21	1995-04-19	쇼다 오사무	아포리포프로틴 b로 이루어진 엔도텔린 전환효소
AU8107094A (en) *	1993-11-16	1995-06-06	Basf Aktiengesellschaft	Endothelin-converting enzyme
GB9325221D0 (en) *	1993-12-09	1994-02-09	Zeneca Ltd	Nucleid acid
GB2284607A (en) *	1993-12-09	1995-06-14	Zeneca Ltd	Mammalian endothelin converting enzyme and cDNA thereof
SE9403915D0 (sv) *	1994-11-14	1994-11-14	Annelie Almstedt	Process A
US5658902A (en) *	1994-12-22	1997-08-19	Warner-Lambert Company	Quinazolines as inhibitors of endothelin converting enzyme
DE60040089D1 (de) *	1999-11-19	2008-10-09	Solvay Pharm Bv	Menschliches homolog aus der familie der metalloproteasen
JP2004524818A (ja) *	2000-10-04	2004-08-19	レキシコン・ジェネティクス・インコーポレーテッド	新規プロテアーゼおよびそれをコードするポリヌクレオチド

1992
- 1992-02-04 CA CA 2100355 patent/CA2100355A1/fr not_active Abandoned
- 1992-02-04 WO PCT/US1992/000906 patent/WO1992013944A1/fr not_active Ceased
- 1992-02-04 EP EP92906293A patent/EP0575405A1/fr not_active Withdrawn

Also Published As

Publication number	Publication date
EP0575405A1 (fr)	1993-12-29
EP0575405A4 (fr)	1994-03-02
WO1992013944A1 (fr)	1992-08-20

Legal Events

Date	Code	Title	Description
2000-02-04	FZDE	Dead

Publication	Publication Date	Title
Ohnaka et al.	1993	Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. OFF.
Beldent et al.	1993	Proteolytic release of human angiotensin-converting enzyme. Localization of the cleavage site.
Morty et al.	2005	Oligopeptidase B from Trypanosoma evansi: a parasite peptidase that inactivates atrial natriuretic factor in the bloodstream of infected hosts
Lanzillo et al.	1985	Angiotensin-converting enzyme from human tissues. Physicochemical, catalytic, and immunological properties.
US5712144A (en)	1998-01-27	Cloned factor C cDNA of the Singapore Horseshoe Crab, Carcinoscorpius rotundicauda and purification of Factor C proenzyme
Georgieva et al.	2008	Comparative analysis of the venom proteomes of Vipera ammodytes ammodytes and Vipera ammodytes meridionalis
Mignogna et al.	1996	BSTI, a trypsin inhibitor from skin secretions of Bombina bombina related to protease inhibitors of nematodes
Condra et al.	1989	Isolation and Structural Charaderization of a Potent Inhibitor of Coagulation Factor Xa from the Leech Haementeria ghilianii
CA2100355A1 (fr)	1992-08-05	Enzyme de conversion de l'endotheline
PL171907B1 (pl)	1997-06-30	Sposób wytwarzania dimeru Apolipoproteiny AL-Milano PL PL PL
Chapus et al.	1981	Stabilization of the C‐terminal part of pig and horse colipase by carboxypeptidase and trypsin inhibitors
Winkler et al.	1986	Purification and characterization of recombinant single-chain urokinase produced in Escherichia coli
Schatteman et al.	2000	Proteolytic activation of purified human procarboxypeptidase U
Cintra et al.	1990	Primary structure and biological activity of bradykinin potentiating peptides from Bothrops insularis snake venom
US5968764A (en)	1999-10-19	Glucose transporter vesicle aminopeptidase
Imada et al.	1988	Atrioactivase, a specific peptidase in bovine atria for the processing of pro-atrial natriuretic factor. Purification and characterization.
EP0263608A2 (fr)	1988-04-13	Protéine ayant des propriétés anticoagulantes et antimétastasiques
Silberring et al.	1989	A novel bovine spinal cord endoprotease with high specificity for dynorphin B
Retzios et al.	1994	Fibrinolytic enzymes from the venoms of Agkistrodon contortrix contortrix and Crotalus basiliscus basiliscus: cleavage site specificity towards the α-chain of fibrin
Halila et al.	1986	Purification of human procollagen type III N-proteinase from placenta and preparation of antiserum
US6025330A (en)	2000-02-15	Inhibitors of fibrin cross-linking and/or transglutaminases
Braun et al.	1988	Preparation and characterization of proteolyzed forms of human α-thrombin
Billadello et al.	1989	Characterization of MB creatine kinase isoform conversion in vitro and in vivo in dogs.
Larsson et al.	1981	The identity and properties of two forms of activated colipase from porcine pancreas
Angermann et al.	1992	Purification and characterization of human salivary‐gland prokallikrein from recombinant baculovirus‐infected insect cells